NORTH AMERICA LIQUID BIOPSY MARKET 2019-2027

MARKET OUTLOOK
After in-depth research conducted by Triton Market Research, the finding shows that the North America liquid biopsy market will grow progressively at a CAGR of 20.25% in terms of revenue for the forecast period of 2019-2027.
The United States and Canada together form the liquid biopsy market in the North American region.
The demand for liquid biopsy is set to increase, owing to the rising number of cancer cases. The United States and Canada have high-tech biopsy technologies that specialize in detecting diseases at the early stages, which can considerably reduce the mortality rates in these countries. According to the CDC report published in March 2016, between 2007 and 2020, the number of cancer deaths is expected to grow up to 15.2% in men and 8.1% in women. The report also found that around 10,000 new lung cancer cases will be seen in women; while, the number of new lung cancer cases will remain the same in men.
Cancer organizations such as the NCI, a part of the NIH, actively play a key role in creating awareness of the importance of early diagnosis of cancer by educating people about the symptoms and the diagnostic tests. The awareness programs have influenced people to opt for diagnostic tests and confirm their disease condition. The rise in prevalence of cancer cases, along with the escalating healthcare expenditure by the governments in the region, will significantly drive the demand for liquid biopsy solutions in North America over the forecast duration.
COMPETITIVE OUTLOOK
Few of the prime players in the liquid biopsy market are Agilent Technologies, Inc., Boston Scientific Corporation, Argon Medical Devices, Inc., B. Braun Melsungen AG, Cintec Medical Ltd., Roche Diagnostics Corporation, Ad-Tech Medical Instrument Corp. and I.M.S. Internazionale Medico Scientifica Srl.

TABLE OF CONTENT
1. NORTH AMERICA LIQUID BIOPSY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHT
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF RIVALRY
2.4. REGULATORY FRAMEWORK
2.5. KEY MARKET TRENDS
2.6. KEY LIQUID BIOPSY INITIATIVES
2.7. MARKET ATTRACTIVENESS INDEX
2.8. MARKET DRIVERS
2.8.1. CANCER CASES IN OLDER POPULACE ARE SIGNIFICANTLY INCREASING
2.8.2. DIAGNOSTIC CENTERS ARE IN DEMAND
2.8.3. TISSUE/TUMOR-AGNOSTIC DRUGS USAGE ARE INCREASING
2.8.4. RISE IN USAGE OF PRECISION MEDICINE
2.9. MARKET RESTRAINTS
2.9.1. HIGH COST OF TEST
2.9.2. LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPs)
2.10. MARKET OPPORTUNITIES
2.10.1. ADVANCEMENT IN TECHNOLOGY
2.10.2. RISING NUMBER OF CANCER PATIENTS
2.11. MARKET CHALLENGES
2.11.1. LACK OF REIMBURSEMENT
2.11.2. SKILLED PROFESSIONALS ARE QUITE LESS IN NUMBERS
3. LIQUID BIOPSY MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. PROSTATE CANCER
3.2. MELANOMA CANCER
3.3. BREAST CANCER
3.4. COLORECTAL CANCER
3.5. LUNG CANCER
3.6. OTHER TYPES OF CANCER
3.7. NON-ONCOLOGY APPLICATIONS
4. LIQUID BIOPSY MARKET OUTLOOK - BY PRODUCT
4.1. CELL-FREE DNA (CFDNA)
4.2. CIRCULATING TUMOR CELLS (CTCS)
4.3. CIRCULATING TUMOR DNA (CTDNA)
4.4. EXTRACELLULAR VESICLES AND OTHERS
5. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PURPOSE
5.1. MONITORING
5.2. THERAPY GUIDANCE
5.3. EARLY DETECTION/SCREENING
5.4. DIAGNOSIS
6. LIQUID BIOPSY INDUSTRY OUTLOOK - BY END-USER
6.1. HOSPITALS
6.2. PHYSICIANS’ OFFICE LABORATORIES
6.3. CLINICAL DIAGNOSTIC LABORATORIES
7. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PLATFORM
7.1. MICROARRAY
7.2. NGS
7.3. PROTEOMICS
7.4. PCR
7.5. OTHER ANALYSIS PLATFORMS
8. LIQUID BIOPSY MARKET OUTLOOK - BY BIOMARKER TYPE
8.1. NUCLEIC ACIDS
8.2. PROTEINS
8.3. EXTRACELLULAR VESICLES
8.4. CELLS
9. LIQUID BIOPSY MARKET OUTLOOK - BY CLINICAL APPLICATION
9.1. TREATMENT MONITORING
9.2. PROGNOSIS & REOCCURRENCE MONITORING
9.3. TREATMENT SELECTION
9.4. DIAGNOSIS & SCREENING
10. LIQUID BIOPSY MARKET - REGIONAL OUTLOOK
10.1. NORTH AMERICA
10.1.1. MARKET BY THERAPEUTIC APPLICATION
10.1.2. MARKET BY CLINICAL APPLICATION
10.1.3. MARKET BY BIOMARKER TYPE
10.1.4. MARKET BY ANALYSIS PLATFORM
10.1.5. MARKET BY ANALYSIS PURPOSE
10.1.6. MARKET BY PRODUCT
10.1.7. MARKET BY END-USER
10.1.8. COUNTRY ANALYSIS
10.1.8.1. THE UNITED STATES
10.1.8.2. CANADA
11. COMPETITIVE LANDSCAPE
11.1. AGILENT TECHNOLOGIES, INC.
11.2. BOSTON SCIENTIFIC CORPORATION
11.3. ARGON MEDICAL DEVICES, INC.
11.4. B. BRAUN MELSUNGEN AG
11.5. CINTEC MEDICAL LTD.
11.6. ROCHE DIAGNOSTICS CORPORATION
11.7. AD-TECH MEDICAL INSTRUMENT CORP.
11.8. I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
11.9. QIAGEN N.V.
11.10. BECTON, DICKINSON
11.11. PLANMECA OY
11.12. BIO-RAD LABORATORIES, INC.
11.13. CARDINAL HEALTH, INC.
11.14. COOK MEDICA, INC.
11.15. FISCHER MEDICAL TECHNOLOGIES LLC
11.16. C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON AND COMPANY)
12. RESEARCH METHODOLOGY & SCOPE
12.1. RESEARCH SCOPE & DELIVERABLES
12.1.1. OBJECTIVES OF STUDY
12.1.2. SCOPE OF STUDY
12.2. SOURCES OF DATA
12.2.1. PRIMARY DATA SOURCES
12.2.2. SECONDARY DATA SOURCES
12.3. RESEARCH METHODOLOGY
12.3.1. EVALUATION OF PROPOSED MARKET
12.3.2. IDENTIFICATION OF DATA SOURCES
12.3.3. ASSESSMENT OF MARKET DETERMINANTS
12.3.4. DATA COLLECTION
12.3.5. DATA VALIDATION & ANALYSIS





LIST OF TABLES
TABLE 1 NORTH AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
TABLE 2 LIQUID BIOPSY BIOMARKER CLASSES
TABLE 3 NORTH AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 4 NORTH AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 5 NORTH AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 6 NORTH AMERICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 7 NORTH AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 8 ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 9 DROPLET DIGITAL PCR INDUSTRIES
TABLE 10 NORTH AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 11 CELL DIFFERENTIATORS
TABLE 12 NORTH AMERICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)


LIST OF FIGURES
FIGURE 1 NORTH AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 2 NORTH AMERICA LIQUID BIOPSY MARKET BY PROSTATE CANCER 2019-2027 ($ MILLION)
FIGURE 3 NORTH AMERICA LIQUID BIOPSY MARKET BY MELANOMA CANCER 2019-2027 ($ MILLION)
FIGURE 4 TYPES OF BREAST CANCER
FIGURE 5 NORTH AMERICA LIQUID BIOPSY MARKET BY BREAST CANCER 2019-2027 ($ MILLION)
FIGURE 6 NORTH AMERICA LIQUID BIOPSY MARKET BY COLORECTAL CANCER 2019-2027 ($ MILLION)
FIGURE 7 NORTH AMERICA LIQUID BIOPSY MARKET BY LUNG CANCER 2019-2027 ($ MILLION)
FIGURE 8 NORTH AMERICA LIQUID BIOPSY MARKET BY OTHER TYPES OF CANCER 2019-2027 ($ MILLION)
FIGURE 9 NORTH AMERICA LIQUID BIOPSY MARKET BY NON-ONCOLOGY APPLICATION 2019-2027 ($ MILLION)
FIGURE 10 NORTH AMERICA LIQUID BIOPSY MARKET BY CELL-FREE DNA (CFDNA) 2019-2027 ($ MILLION)
FIGURE 11 NORTH AMERICA LIQUID BIOPSY MARKET BY CIRCULATING TUMOR CELLS (CTCS) 2019-2027 ($ MILLION)
FIGURE 12 NORTH AMERICA LIQUID BIOPSY MARKET BY CIRCULATING TUMOR DNA (CTDNA) 2019-2027 ($ MILLION)
FIGURE 13 NORTH AMERICA LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES AND OTHERS 2019-2027 ($ MILLION)
FIGURE 14 NORTH AMERICA LIQUID BIOPSY MARKET BY MONITORING 2019-2027 ($ MILLION)
FIGURE 15 NORTH AMERICA LIQUID BIOPSY MARKET BY THERAPY GUIDANCE 2019-2027 ($ MILLION)
FIGURE 16 NORTH AMERICA LIQUID BIOPSY MARKET BY EARLY DETECTION/SCREENING 2019-2027 ($ MILLION)
FIGURE 17 NORTH AMERICA LIQUID BIOPSY MARKET BY DIAGNOSIS 2019-2027 ($ MILLION)
FIGURE 18 NORTH AMERICA LIQUID BIOPSY MARKET BY HOSPITALS 2019-2027 ($ MILLION)
FIGURE 19 NORTH AMERICA LIQUID BIOPSY MARKET BY PHYSICIANS’ OFFICE LABORATORIES 2019-2027 ($ MILLION)
FIGURE 20 NORTH AMERICA LIQUID BIOPSY MARKET BY CLINICAL DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 21 NORTH AMERICA LIQUID BIOPSY MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 22 NORTH AMERICA LIQUID BIOPSY MARKET BY NGS 2019-2027 ($ MILLION)
FIGURE 23 NORTH AMERICA LIQUID BIOPSY MARKET BY PROTEOMICS 2019-2027 ($ MILLION)
FIGURE 24 NORTH AMERICA LIQUID BIOPSY MARKET BY PCR 2019-2027 ($ MILLION)
FIGURE 25 NORTH AMERICA LIQUID BIOPSY MARKET BY OTHER ANALYSIS PLATFORM 2019-2027 ($ MILLION)
FIGURE 26 NORTH AMERICA LIQUID BIOPSY MARKET BY NUCLEIC ACIDS 2019-2027 ($ MILLION)
FIGURE 27 NORTH AMERICA LIQUID BIOPSY MARKET BY PROTEINS 2019-2027 ($ MILLION)
FIGURE 28 NORTH AMERICA LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES 2019-2027 ($ MILLION)
FIGURE 29 NORTH AMERICA LIQUID BIOPSY MARKET BY CELLS 2019-2027 ($ MILLION)
FIGURE 30 NORTH AMERICA LIQUID BIOPSY MARKET BY TREATMENT MONITORING 2019-2027 ($ MILLION)
FIGURE 31 NORTH AMERICA LIQUID BIOPSY MARKET BY PROGNOSIS & REOCCURRENCE MONITORING 2019-2027 ($ MILLION)
FIGURE 32 NORTH AMERICA LIQUID BIOPSY MARKET BY TREATMENT SELECTION 2019-2027 ($ MILLION)
FIGURE 33 NORTH AMERICA LIQUID BIOPSY MARKET BY DIAGNOSIS & SCREENING 2019-2027 ($ MILLION)
FIGURE 34 NORTH AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 35 THE UNITED STATES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 36 NEW CANCER CASES & CANCER DEATHS IN THE US 2016-2020 (PER 100,000 PEOPLE)
FIGURE 37 CANADA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)